KLHDC7B inhibitors are a class of chemical compounds designed to target and inhibit the function of the KLHDC7B protein, which belongs to the family of kelch domain-containing proteins. These proteins are involved in a variety of cellular processes, often acting as scaffolds to organize protein complexes or participating in the ubiquitination pathway, where proteins are marked for degradation. The specific role of KLHDC7B within this family is still being elucidated, but it is known to interact with other proteins involved in regulatory functions within the cell. Inhibitors of KLHDC7B typically work by binding to the protein and blocking its interaction with these other molecules, thereby preventing it from fulfilling its normal cellular role.
The design of KLHDC7B inhibitors typically involves identifying small molecules that can specifically bind to the kelch repeat domains of the protein. These domains are known for their ability to form β-propeller structures, which provide a binding interface for interaction with other proteins. Inhibitors are generally crafted to fit into the binding pockets of these structures, disrupting the interactions necessary for KLHDC7B's function. Due to the complexity of protein-protein interactions, developing selective and potent inhibitors requires detailed understanding of KLHDC7B's structure and function, often aided by techniques such as X-ray crystallography or molecular docking studies. This level of specificity is crucial to ensure that the inhibitors target only KLHDC7B without affecting other members of the kelch domain protein family.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor, impacting protein degradation and ubiquitin-proteasome pathways. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Another proteasome inhibitor, used to study ubiquitin-dependent protein degradation. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A specific proteasome inhibitor, used clinically for certain types of cancer. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
Inhibits the NEDD8-activating enzyme, affecting protein ubiquitination and stability. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
An inhibitor of actin polymerization, affecting cytoskeletal dynamics. | ||||||
Colchicine | 64-86-8 | sc-203005 sc-203005A sc-203005B sc-203005C sc-203005D sc-203005E | 1 g 5 g 50 g 100 g 500 g 1 kg | $100.00 $321.00 $2289.00 $4484.00 $18207.00 $34749.00 | 3 | |
Binds to tubulin and inhibits microtubule polymerization, impacting cell division and cytoskeletal structure. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
A microtubule-depolymerizing agent, used to disrupt microtubule dynamics. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A ROCK inhibitor, affecting actin cytoskeleton organization and cell motility. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $41.00 $74.00 $221.00 $247.00 $738.00 $1220.00 | 39 | |
Stabilizes microtubules, preventing their disassembly which is essential for cell division. | ||||||
(S)-(−)-Blebbistatin | 856925-71-8 | sc-204253 sc-204253A sc-204253B sc-204253C | 1 mg 5 mg 10 mg 25 mg | $72.00 $265.00 $495.00 $968.00 | ||
Inhibits myosin II, affecting muscle contraction and cell motility. | ||||||